Article Data

  • Views 505
  • Dowloads 137


Open Access Special Issue

Role of sentinel lymph node in endometrial cancer: rationale and surgical aspects, a review of the literature

  • Giuseppe Marino1,*,
  • Tommaso Grassi1
  • Giampaolo Di Martino1
  • Gaetano Trezzi1
  • Marco Adorni1
  • Luca Bazzurini1
  • Fabio Landoni1

1Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milan-Bicocca, 20126 Monza, Italy

DOI: 10.31083/j.ejgo4301014 Vol.43,Issue 1,February 2022 pp.106-114

Submitted: 01 November 2021 Accepted: 24 November 2021

Published: 15 February 2022

(This article belongs to the Special Issue Endometrial Cancer)

*Corresponding Author(s): Giuseppe Marino E-mail:


Endometrial carcinoma is the most common gynecological cancer in Europe, with 130,000 new cases per year, and the incidence has been rising with aging and increased obesity of the population. Most women with endometrial cancer will present with early-stage disease, with a tumor confined to the uterus and without metastasis, and the first approach is surgery. Approximately 10% to 15% of these patients have a metastatic nodal disease, which is why guidelines have always emphasized the importance of lymphadenectomy to stratify the risk and tailor adjuvant treatment. However, comprehensive lymphadenectomy is related to significant morbidity and seems not to improve either progression-free or overall survival in these patients. Lymphatic mapping with sentinel lymph node biopsy has emerged as an alternative and an optimal compromise instead of systematic lymphadenectomy. This review presents the current evidence supporting sentinel lymph node biopsy in patients with endometrial cancer.


Endometrial cancer; Lymph nodes; Sentinel lymph node; SLN mapping

Cite and Share

Giuseppe Marino,Tommaso Grassi,Giampaolo Di Martino,Gaetano Trezzi,Marco Adorni,Luca Bazzurini,Fabio Landoni. Role of sentinel lymph node in endometrial cancer: rationale and surgical aspects, a review of the literature. European Journal of Gynaecological Oncology. 2022. 43(1);106-114.


[1] World Health Organization. GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. 2020. Available at: ers/24-Corpus-uteri-fact-sheet.pdf (Accessed: 29 July 2020).

[2] PDQ Adult Treatment Editorial Board. Endometrial Cancer Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. National Cancer Institute (US): Bethesda (MD). 2002.

[3] Orr JW, Holloway RW, Orr PF, Holimon JL. Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecologic Oncology. 1991; 42: 209–216.

[4] Partridge EE, Shingleton HM, Menck HR. The National Cancer Data Base report on endometrial cancer. Journal of Surgical Oncology. 1996; 61: 111–123.

[5] Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenec-tomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. Journal of the National Cancer Institute. 2008; 100: 1707–1716.

[6] ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, et al. Efficacy of systematic pelvic lymphadenec-tomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373: 125–136.

[7] Achouri A, Huchon C, Bats AS, Bensaid C, Nos C, Lécuru F. Complications of lymphadenectomy for gynecologic cancer. European Journal of Surgical Oncology. 2013; 39: 81–86.

[8] Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecologic Oncology. 2006; 103: 714–718.

[9] Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Job-sen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000; 355: 1404–1411.

[10] Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecologic Oncology. 2008; 109: 11–18.

[11] de Hullu JA, Hollema H, Piers DA, Verheijen RH, van Diest PJ, Mourits MJ, et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. Journal of Clinical Oncology. 2000; 18: 2811–2816.

[12] Glaser G, Dinoi G, Multinu F, Yost K, Al Hilli M, Larish A, et al. Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer. International Journal of Gynecological Cancer. 2021; 31: 85–91.

[13] Nagar H, Wietek N, Goodall RJ, Hughes W, Schmidt-Hansen M, Morrison J. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. The Cochrane Database of Systematic Reviews. 2021; 6: CD013021.

[14] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Uterine Neoplasms. Version 3. 2021. Available at: an_gls/pdf/uterine.pdf (Accessed: 22 November 2021).

[15] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2021; 31: 12–39.

[16] Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Archives of Surgery. 1992; 127: 392–399.

[17] Cody HS, Hill AD, Tran KN, Borgen PI. Credentialing for breast lymphatic mapping: how many cases are enough? Annals of Surgery. 1999; 229: 723–726.

[18] Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecologic Oncology. 1996; 62: 169–173.

[19] Moloney K, Janda M, Frumovitz M, Leitao M, Abu-Rustum NR, Rossi E, et al. Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer. 2021; 31: 647–655.

[20] Barlin JN, Khoury-Collado F, Kim CH, Leitao Jr MM, Chi DS, Sonoda Y, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecologic Oncology. 2012; 125: 531–535.

[21] Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lym-phadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. The Lancet Oncology. 2017; 18: 384–392.

[22] Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Mar-ret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). The Lancet Oncology. 2011;12: 469–476.

[23] Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology. 2017; 216: 459–476.e10.

[24] Frumovitz M, Plante M, Lee PS, Sandadi S, Lilja JF, Escobar PF, et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, noninferiority trial. The Lancet Oncology. 2018; 19: 1394–1403.

[25] Persson J, Salehi S, Bollino M, Lönnerfors C, Falconer H, Geppert B. Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial) - the final step towards a paradigm shift in surgical staging. European Journal of Cancer. 2019; 116: 77–85.

[26] Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, et al. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. JAMA Surgery. 2021; 156: 157–164.

[27] Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecologic Oncology. 2017; 146: 234–239.

[28] Touhami O, Grégoire J, Renaud MC, Sebastianelli A, Plante M. Performance of sentinel lymph node (SLN) mapping in high-risk endometrial cancer. Gynecologic Oncology. 2017; 147: 549–553.

[29] Daraï E, Dubernard G, Bats AS, Heitz D, Mathevet P, Marret H, et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecologic Oncology. 2015; 136: 54–59.

[30] Buda A, Gasparri ML, Puppo A, Mereu L, De Ponti E, Di Martino G, et al. Lymph node evaluation in high-risk early stage endometrial cancer: A multiinstitutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy. Gynecologic Oncology. 2018; 150: 261–266.

[31] Buda A, Restaino S, Di Martino G, De Ponti E, Monterossi G, Dinoi G, et al. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study. European Journal of Surgical Oncology. 2018; 44: 1562–1567.

[32] Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecologic Oncology. 2016; 140: 394–399.

[33] Schlappe BA, Weaver AL, Ducie JA, Eriksson AGZ, Dowdy SC, Cliby WA, et al. Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecologic Oncology. 2018; 151: 235–242.

[34] Bogani G, Papadia A, Buda A, Casarin J, Di Donato V, Gasparri ML, et al. Sentinel node mapping vs. sentinel node mapping plus backup lymphadenectomy in high-risk endometrial cancer patients: Results from a multiinstitutional study. Gynecologic Oncology. 2021; 161: 122–129.

[35] Basaran D, Bruce S, Aviki EM, Mueller JJ, Broach VA, Cadoo K, et al. Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecologic Oncology. 2020; 156: 70–76.

[36] Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, Soslow RA, Dao F, Sonoda Y, et al. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecologic Oncology. 2009; 113: 163–169.

[37] Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Po-dratz KC. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? American Journal of Obstetrics and Gy-necology. 2000; 182: 1506–1519.

[38] Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, et al. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstetrics and Gynecology. 2018; 132: 52–58.

[39] Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA, et al. Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology. 2016; 23: 196–202.

[40] Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, et al. Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology. 2017; 24: 1965–1971.

[41] Grassi T, Mariani A, Cibula D, Soliman PT, Suman VJ, Weaver AL, et al. A prospective multicenter international single-arm ob-servational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial). International Journal of Gynecological Cancer. 2020; 30: 1627–1632.

[42] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27: 16–41.

[43] Kim CH, Soslow RA, Park KJ, Barber EL, Khoury-Collado F, Barlin JN, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. International Journal of Gynecological Cancer. 2013; 23: 964–970.

[44] Han G, Lim D, Leitao MM Jr, Abu-Rustum NR, Soslow RA. Histological features associated with occult lymph node metas-tasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology. 2014; 64: 389–398.

[45] McCready DR, Yong WS, Ng AK, Miller N, Done S, Youngson

B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false negative rates. Journal of the National Cancer Institute. 2004; 96: 873–875.

[46] Buda A, Di Martino G, Restaino S, De Ponti E, Monterossi G, Giuliani D, et al. The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing sentinel lymph nodes mapping algorithm and selective lymphadenectomy: an Italian retrospective analysis of two reference centers. Gynecologic Oncology. 2017; 147: 528–534.

[47] Ducie JA, Eriksson AGZ, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecologic Oncology. 2017; 147: 541–548.

[48] Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncology. 2017; 146: 405–415.

[49] Todo Y, Kato H, Okamoto K, Minobe S, Yamashiro K, Sakuragi N. Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. Journal of Gynecologic Oncology. 2016; 27: e1.

[50] St Clair CM, Eriksson AG, Ducie JA, Jewell EL, Alektiar KM, Hensley ML, et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Annals of Surgical Oncology. 2016; 23: 1653–1659.

[51] Plante M, Stanleigh J, Renaud MC, Sebastianelli A, Grondin K, Grégoire J. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecologic Oncology. 2017; 146: 240–246.

[52] Ghoniem K, Larish AM, Dinoi G, Zhou XC, Alhilli M, Wallace S, et al. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multiinstitutional study. Gynecologic Oncology. 2021; 162: 590–598.

[53] Buda A, Crivellaro C, Elisei F, Di Martino G, Guerra L, De Ponti E, et al. Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer (99m)Tc and/or blue dye. Annals of Surgical Oncology. 2016; 23: 2183–2191.

[54] How J, Gotlieb WH, Press JZ, Abitbol J, Pelmus M, Ferenczy A, et al. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecologic Oncology. 2015; 137: 436–442.

[55] Jewell EL, Huang JJ, Abu-Rustum NR, Gardner GJ, Brown CL, Sonoda Y, et al. Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and nearinfrared fluorescence imaging for uterine and cervical malignancies. Gynecologic Oncology. 2014; 133: 274–277.

[56] Rozenholc A, Samouelian V, Warkus T, Gauthier P, Provencher D, Sauthier P, et al. Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. Gynecologic Oncology. 2019; 153: 500–504.

[57] Backes FJ, Cohen D, Salani R, Cohn DE, O’Malley DM, Fanning E, et al. Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecologic Oncology. 2019; 153: 496–499.

[58] Khoury-Collado F, Abu-Rustum NR. Lymphatic mapping in endometrial cancer: a literature review of current techniques and results. International Journal of Gynecological Cancer. 2008; 18: 1163–1168.

[59] Abu-Rustum NR, Khoury-Collado F, Gemignani ML. Techniques of sentinel lymph node identification for early-stage cer-ical and uterine cancer. Gynecologic Oncology. 2008; 111: S44–50.

[60] Abu-Rustum NR. Sentinel Lymph Node Mapping for Endometrial Cancer: A Modern Approach to Surgical Staging. Journal of the National Comprehensive Cancer Network. 2014; 12: 288–297.

[61] Abu-Rustum NR, Gomez JD, Alektiar KM, Soslow RA, Hensley ML, Leitao MM Jr, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic Oncology. 2009; 115: 236–238.

[62] Ditto A, Casarin I, Pinelli C, Perrone AM, Scollo P, Martinelli F, et al. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. European Journal of Cancer. 2020; 140: 1–10.

[63] Martinelli F, Ditto A, Bogani G, Leone Roberti Maggiore U, Signorelli M, et al. Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers. International Journal of Gynecological Cancer. 2020; 30: 332–338.

[64] Angeles MA, Migliorelli F, Vidal-Sicart S, Saco A, Ordi J, Ros C, et al. Paraaortic sentinel lymph node detection in intermediate and high-risk endometrial cancer by transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR). Journal of Gynecologic Oncology. 2021; 32: e52.

[72] Euscher ED, Malpica A. Gynaecological malignancies and sentinel lymph node mapping: an update. Histopathology. 2020; 76: 139–150.

[73] Holloway RW, Gupta S, Stavitzski NM, Zhu X, Takimoto EL, Gubbi A, et al. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecologic Oncology. 2016; 141: 206–210.

[74] Euscher E, Sui D, Soliman P, Westin S, Ramalingam P, Bassett R, et al. Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods. International Journal of Gynecological Pathology. 2018; 37: 242–251.

[75] Grassi T, Dell’Orto F, Jaconi M, Lamanna M, De Ponti E, Paderno M, et al. Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial cancers. International Gournal of Gynecological Cancer. 2020; 30: 1404–1410.

[76] Burg LC, Hengeveld EM, In ’t Hout J, Bulten J, Bult P, Zusterzeel PLM. Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review. International Journal of Gynecological Cancer. 2021; 31: 744–753.

[77] Fanfani F, Monterossi G, Di Meo ML, La Fera E, Dell’Orto F, Gioè A, et al. Standard ultra-staging compared to one-step nu-cleic acid amplification for the detection of sentinel lymph node metastasis in endometrial cancer patients: a retrospective cohort comparison. International Journal of Gynecological Cancer. 2020; 30: 372–377.

[78] Diestro MD, Berjón A, Zapardiel I, Yébenes L, Ruiz I, Lekuona A, et al. One-Step Nucleic Acid Amplification (OSNA) of Sentinel Lymph Node in Early-Stage Endometrial Cancer: Spanish Multicenter Study (ENDO-OSNA). Cancers. 2021; 13: 4465.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time